A Fortune 500 Pharma Company

Fresh Gravity implemented a Reltio MDM solution to master Investigators, Sites, and Clinical Studies, saving approximately USD $2M through the automation and reduction of low value manual data quality remediation and de-duplication efforts. This solution improved operational efficiencies relative to the use of master data to over a dozen downstream systems across R&D and Regulatory functions.

Problem

Our client used Veeva’s CTMS as a primary system of record for Investigators, HCOs, Studies and Study Sites. However, due to a lack of duplicate identification and a lenient governance process, inaccurate data was propagated to multiple downstream systems leading to issues in selecting the best-choice Investigators and Study Sites for upcoming trials. In addition, they did not have tools in place to fully leverage data from third-part data providers to address the duplicate data prevalent in the ecosystem.

Solution

As a part of implementing a Master Data Management solution, our team re-engineered the business process and automated data flow from site/investigator selection to enrichment from DrugDev and Location verification services using Google API to management of the data in their CTMS. Our Data Governance experts closely collaborated with business stakeholders and data owners to establish a data quality and data stewardship/governance management program that had data-quality-at-source as the foundational principal.

Impact

The MDM-led transformation resulted in saving approximately USD 2M through the automation and reduction of low value manual data quality remediation and de-duplication efforts. It also saved nearly 1980 manual hours annually. More importantly, downstream operational processes were optimized and simplified due to the propagation of validated and verified high quality data to at least 13 R&D systems.